Modified Citrus Pectin
MCP · Citrus pectin · Pectasol
Snapshot
| Indications | Contraindications |
|---|---|
Modified citrus pectin (MCP) is citrus pectin processed to a lower molecular weight, and it acts as a competitive antagonist of galectin-32. It is used for two things that follow from that profile.2 Men with biochemically relapsed prostate cancer after local therapy take it to lengthen prostate-specific antigen (PSA) doubling time1, 2, and people with metal exposure take it to increase excretion of lead, arsenic, and cadmium.
The prostate evidence comes from single-arm phase 2 studies that reported improved PSA doubling time without grade 3 or 4 toxicity2, 3. The metal data come from small pilot studies measuring excretion, and a placebo-controlled trial in knee osteoarthritis found no significant benefit over placebo. In obese rats with myocardial ischemia, a 2025 study found MCP reduced expression of fibrosis-related genes through galectin-3 inhibition; no human trial has tested it. Many products list modified citrus pectin, mostly as capsules and powders; see Form comparison.
United States product labels carry two kinds of caution: some say not to take it when pregnant or nursing7, and others direct people with diabetes or an intestinal disorder to consult a health care professional first7.
Last updated October 15, 2026. Read how we make monographs.
In the full monograph
33 sources, 20 studies
- When to useThe situations practitioners use it for, each with the reason and the study behind it.
- SafetyWho should avoid it, who needs extra care, and the side effects reported in studies.
- InteractionsThe medicines and supplements it interacts with, the effect of each, and what labeling says to watch.
- Protocol notesThe doses used in studies, how and when they were taken, and how the forms on the market compare.
- How it worksWhat it is and how it works in the body, in plain terms.
- Published studiesThe studies behind each use, popular claims checked against them, and trials still under way.
- Word of mouthWhat patients and practitioners report online, kept separate from the clinical evidence.
- Clinical perspectiveA closing read of where the evidence is solid, where it is thin, and what has not been studied.
Sources
- 1Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.pubmed.ncbi.nlm.nih.govGuess, Scholz, Strum et al. · Prostate cancer and prostatic diseases · 2003 · Pubmed
- 2Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.pubmed.ncbi.nlm.nih.govKeizman, Frenkel, Peer et al. · Nutrients · 2021 · Pubmed
- 3Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.pubmed.ncbi.nlm.nih.govKeizman, Frenkel, Peer et al. · Nutrients · 2023 · Pubmed
- 4The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels.pubmed.ncbi.nlm.nih.govZhao, Liang, Fan et al. · Alternative therapies in health and medicine · 2008 · Pubmed
- 5The effect of modified citrus pectin on urinary excretion of toxic elements.pubmed.ncbi.nlm.nih.govEliaz, Hotchkiss, Fishman et al. · Phytotherapy research : PTR · 2006 · Pubmed
- 6Modified Citrus Pectin / Alginate Dietary Supplement Increased Fecal Excretion of Uranium: A Family.pubmed.ncbi.nlm.nih.govEliaz, Weil, Schwarzbach et al. · Alternative therapies in health and medicine · 2019 · Pubmed
- 7US product labelsdsld.od.nih.govWarnings printed on US dietary supplement labels with this ingredient, from the NIH Office of Dietary Supplements' Dietary Supplement Label Database (DSLD). Manufacturers' precautions, not evidence of harm